Literature DB >> 34220013

Relationship of Brain-Derived Neurotrophic Factor with Interleukin-23, Testosterone and Disease Severity in Schizophrenia.

Priya Allimuthu1, Hanumanthappa Nandeesha1, Raghavi Chinniyappan1, Balaji Bhardwaz1,2, Jesudas Blessed Raj1.   

Abstract

Hormonal imbalance, inflammation and alteration in synaptic plasticity are reported to play a crucial role in the pathogenesis of schizophrenia. The objective of the study was to assess the serum levels of brain derived neurotrophic factor (BDNF) and its association with interleukin-23 (IL-23), testosterone and disease severity in schizophrenia. 40 cases and 40 controls were included in the study. Serum levels of BDNF, IL-23 and testosterone were estimated in all the subjects. Disease severity was assessed using Positive and Negative Syndrome Scale (PANSS). The study was designed in Tertiary care hospital, South India. The results were compared between two groups using Mann-Whitney U test. Spearman Correlation analysis was used to assess the association between biochemical parameters and PANSS. Interleukin-23 and testosterone were significantly increased and BDNF was significantly reduced in schizophrenia cases when compared with controls. BDNF was negatively correlated with IL-23 (r = - 400, p = 0.011), positive symptom subscale (r = - 0.393, p = 0.012), general psychopathology score subscale (r = - 407, p = 0.009) and total symptom subscale (r = - 404, p = 0.010). There was no significant association of IL-23 and testosterone with disease severity in schizophrenia cases. BDNF was reduced in schizophrenia cases and negatively associated with interleukin-23 and disease severity scores. © Association of Clinical Biochemists of India 2020.

Entities:  

Keywords:  Brain derived neurotrophic factor; Inflammation; Positive and Negative symptom score; Schizophrenia; Testosterone

Year:  2020        PMID: 34220013      PMCID: PMC8215017          DOI: 10.1007/s12291-020-00880-y

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  28 in total

1.  Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia.

Authors:  Xiang Yang Zhang; Jun Liang; Da Chun Chen; Mei Hong Xiu; Fu De Yang; Therese A Kosten; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2012-01-26       Impact factor: 4.530

2.  Testosterone levels and clinical features of schizophrenia with emphasis on negative symptoms and aggression.

Authors:  Mirna Sisek-Šprem; Aida Križaj; Vlado Jukić; Milan Milošević; Zrinka Petrović; Miroslav Herceg
Journal:  Nord J Psychiatry       Date:  2014-08-25       Impact factor: 2.202

3.  Plasma levels of Th17-related cytokines and complement C3 correlated with aggressive behavior in patients with schizophrenia.

Authors:  Haozhe Li; Qinting Zhang; Ningning Li; Fan Wang; Hui Xiang; Zongfeng Zhang; Yousong Su; Yueqi Huang; Shengyu Zhang; Guoqing Zhao; Rubai Zhou; Ling Mao; Zhiguang Lin; Weixiong Cai; Yiru Fang; Bin Xie; Min Zhao; Wu Hong
Journal:  Psychiatry Res       Date:  2016-11-02       Impact factor: 3.222

Review 4.  Neuroprotective role of testosterone in the nervous system.

Authors:  M Białek; P Zaremba; K K Borowicz; S J Czuczwar
Journal:  Pol J Pharmacol       Date:  2004 Sep-Oct

Review 5.  Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis.

Authors:  M J Green; S L Matheson; A Shepherd; C S Weickert; V J Carr
Journal:  Mol Psychiatry       Date:  2010-08-24       Impact factor: 15.992

Review 6.  Interleukin-23: as a drug target for autoimmune inflammatory diseases.

Authors:  Chunlei Tang; Shu Chen; Hai Qian; Wenlong Huang
Journal:  Immunology       Date:  2012-02       Impact factor: 7.397

7.  Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls.

Authors:  Eiji Shimizu; Kenji Hashimoto; Hiroyuki Watanabe; Naoya Komatsu; Naoe Okamura; Kaori Koike; Naoyuki Shinoda; Michiko Nakazato; Chikara Kumakiri; Sin-ichi Okada; Masaomi Iyo
Journal:  Neurosci Lett       Date:  2003-11-13       Impact factor: 3.046

8.  Inducible IL-23p19 expression in human microglia via p38 MAPK and NF-kappaB signal pathways.

Authors:  Yonghai Li; Niansheng Chu; Aihua Hu; Bruno Gran; Abdolmohamad Rostami; Guang-Xian Zhang
Journal:  Exp Mol Pathol       Date:  2007-10-17       Impact factor: 3.362

Review 9.  The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia.

Authors:  Oliver D Howes; Robert McCutcheon; Michael J Owen; Robin M Murray
Journal:  Biol Psychiatry       Date:  2016-08-06       Impact factor: 13.382

10.  Comparison of Plasma Neurosteroid and Prolactin Levels in Patients with Schizophrenia and Healthy Individuals.

Authors:  Forough Riahi; Maryam Izadi-Mazidi; Ali Ghaffari; Elham Yousefi; Shahram Khademvatan
Journal:  Scientifica (Cairo)       Date:  2016-05-10
View more
  2 in total

Review 1.  Linking Inflammation, Aberrant Glutamate-Dopamine Interaction, and Post-synaptic Changes: Translational Relevance for Schizophrenia and Antipsychotic Treatment: a Systematic Review.

Authors:  Andrea de Bartolomeis; Annarita Barone; Licia Vellucci; Benedetta Mazza; Mark C Austin; Felice Iasevoli; Mariateresa Ciccarelli
Journal:  Mol Neurobiol       Date:  2022-08-13       Impact factor: 5.682

2.  The interleukin-6/interleukin-23/T helper 17-axis as a driver of neuro-immune toxicity in the major neurocognitive psychosis or deficit schizophrenia: A precision nomothetic psychiatry analysis.

Authors:  Hussein Kadhem Al-Hakeim; Ali Fattah Al-Musawi; Abbas Al-Mulla; Arafat Hussein Al-Dujaili; Monojit Debnath; Michael Maes
Journal:  PLoS One       Date:  2022-10-18       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.